TY - JOUR
T1 - Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer
AU - Wang, Taishu
AU - Wang, Duchuang
AU - Zhang, Yue
AU - Zhang, Jinrui
AU - Sun, Xiuna
AU - Wu, Yue
AU - Wang, Shanshan
AU - Zhang, Yang
AU - Xu, Lu
AU - Kong, Qingxia
AU - Gao, Yurou
AU - Wu, Yueguang
AU - Liu, Fang
AU - Liu, Shuyan
AU - Zhang, Yingqiu
AU - Lei, Ting
AU - Liu, Han
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/12
Y1 - 2018/12
N2 - Lung cancer is a leading cause of death worldwide, with mutations in EGFR frequently detected that render this receptor tyrosine kinase constantly active. Targeted therapy against EGFR has proved effective in lung cancer treatment, but secondary mutations in EGFR frequently cause drug resistance. In the efforts made to investigate alternative ways to inhibit mutant EGFR, we observed that the dynamin inhibitor dynasore effectively suppressed the exon 19-deleted mutant of EGFR. This agent inhibited cell proliferation, colony formation, cell migration, and cell cycle progression of HCC827 and H1650 cells driven by the exon 19-deleted EGFR mutant. From a mechanistic point of view, dynasore suppressed the activation of AKT and MEK in HCC827 and H1650 cells. However, dynasore failed to alter the subcellular distribution of EGFR, and another dynamin inhibitor, dyngo-4a, did not phenocopy the effects of dynasore, suggesting a dynamin activity-independent effect of dynasore. Finally, we show that dynasore induced the potent ubiquitylation of the exon 19-deleted mutant of EGFR. Our observations will shed light on the development of alternative therapeutic strategies that target mutant EGFR in lung cancer.
AB - Lung cancer is a leading cause of death worldwide, with mutations in EGFR frequently detected that render this receptor tyrosine kinase constantly active. Targeted therapy against EGFR has proved effective in lung cancer treatment, but secondary mutations in EGFR frequently cause drug resistance. In the efforts made to investigate alternative ways to inhibit mutant EGFR, we observed that the dynamin inhibitor dynasore effectively suppressed the exon 19-deleted mutant of EGFR. This agent inhibited cell proliferation, colony formation, cell migration, and cell cycle progression of HCC827 and H1650 cells driven by the exon 19-deleted EGFR mutant. From a mechanistic point of view, dynasore suppressed the activation of AKT and MEK in HCC827 and H1650 cells. However, dynasore failed to alter the subcellular distribution of EGFR, and another dynamin inhibitor, dyngo-4a, did not phenocopy the effects of dynasore, suggesting a dynamin activity-independent effect of dynasore. Finally, we show that dynasore induced the potent ubiquitylation of the exon 19-deleted mutant of EGFR. Our observations will shed light on the development of alternative therapeutic strategies that target mutant EGFR in lung cancer.
KW - Dynasore
KW - EGFR
KW - Lung cancer
KW - Signalling
KW - Ubiquitylation
UR - http://www.scopus.com/inward/record.url?scp=85054179395&partnerID=8YFLogxK
U2 - 10.1016/j.biocel.2018.09.017
DO - 10.1016/j.biocel.2018.09.017
M3 - Article
C2 - 30268747
AN - SCOPUS:85054179395
SN - 1357-2725
VL - 105
SP - 1
EP - 12
JO - International Journal of Biochemistry and Cell Biology
JF - International Journal of Biochemistry and Cell Biology
ER -